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ABSTRACT: Lipidic formulations (LFs) are increasingly utilized for the delivery of drugs that belong to class II of the
Biopharmaceutics Classiﬁcation System (BCS). The current work proposes, for the ﬁrst time, the combination of in vitro lipolysis
and microsomal metabolism studies for the quantitative prediction of human oral bioavailability of BCS II drugs administered in
LFs. Marinol and Neoral were selected as model LFs, and their observed oral bioavailabilities (Fobserved) were obtained from
published clinical studies in humans. Two separate lipolysis buﬀers, diﬀering in the level of surfactant concentrations, were used
for digestion of the LFs. The predicted fraction absorbed (Fabs) was calculated by measuring the drug concentration in the
micellar phase after completion of the lipolysis process. To determine ﬁrst-pass metabolism (Fg·Fh), drug depletion studies with
human microsomes were performed. Clearance values were determined by applying the “in vitro half-life” approach. The
estimated Fabs and Fg·Fh values were combined for the calculation of the predicted oral bioavailability (Fpredicted). Results showed
that there was a strong correlation between Fobserved and Fpredicted values only when Fabs was calculated using a buﬀer with
surfactant concentrations closer to physiological conditions. The general accuracy of the predicted values suggests that the novel
in vitro lipolysis/metabolism approach could quantitatively predict the oral bioavailability of lipophilic drugs administered in LFs.
KEYWORDS: in vitro lipolysis, microsomal metabolism, IVIVC, oral bioavailability, Δ9-tetrahydrocannabinol, cyclosporine A
1. INTRODUCTION
Current experimental and computational drug discovery
techniques have exponentially increased the number of
potential pharmacologically active drug candidates.1 However,
the majority of these new chemical compounds suﬀer from low
aqueous solubility,2 and therefore, their bioavailability could be
limited if they are intended for oral administration. Lipid-based
formulations (LFs) are increasingly utilized for the delivery of
poorly water-soluble drugs. Mechanisms by which LFs may
enhance the oral bioavailability of poorly water-soluble drugs
include promoting drug solubilization in the intestinal milieu,
delaying gastric emptying and transit time, inhibiting intestinal
eﬄux transporters, reducing CYP-mediated gut wall metabo-
lism, and increasing intestinal lymphatic transport of highly
lipophilic compounds.3−9 The in vitro assessment of LFs is
challenging, since traditional dissolution testing lacks the
ﬂexibility to deal with the complicated interplay between lipid
digestion products, drug-loading, and micellar solubilization.10
In this regard, in vitro lipolysis is capable of mimicking the
intestinal lipid digestion process and, therefore, is a suitable
technique for assessing the fate of drugs administered in
LFs.11−13 Pancreatic lipase is responsible for the in vitro
lipolysis process. This enzyme hydrolyses the triglycerides in
the formulation, releasing fatty acids and prompting a drop in
pH. A pH-stat titrator is used to control this drop in pH and to
keep it within the physiological range.14 Once the lipolysis
process is complete, the resulting mixture is separated into
discrete layers. The most relevant of these phases is the
aqueous one, since it contains micellar structures within which
hydrophobic molecules are solubilized. The general assumption
made by researchers working with the model is that the fraction
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of drug dose solubilized in the micellar phase is most readily
available for absorption.
Previous lipolysis studies have focused on rank-ordering the
performance of LFs.12,15−18 This was done by correlating the
percentage of drug solubilized in the micellar phase with the
area under the plasma concentration−time curve or the
maximum concentration obtained after oral administration of
the tested LF to animals (rats, mini-pigs, or dogs). As an
example, Dahan and Hoﬀman13,19 reported linear relationships
(R2 > 0.98, 0.99) for progesterone and griseofulvin when
administered to rats in short-, medium-, and long-chain
triglycerides. However, no linear in vitro in vivo correlation
(IVIVC) was found for the other two tested drugs, vitamin D3
and dexamethasone. To the best of our knowledge, there are no
publications describing the correlation between the in vitro
lipolysis data of LFs and drug exposure in humans.
LFs are mainly used for the delivery of drugs that belong to
class II of the Biopharmaceutics Classiﬁcation System (BCS),
i.e. drugs characterized by high permeability and low aqueous
solubility. Intestinal micellar solubilization and ﬁrst-pass
metabolism (rather than membrane permeability) are the
main barriers to the oral bioavailability of BCS II drugs. To
note, in the case of highly lipophilic compounds, the
contribution of intestinal lymphatic transport to overall oral
bioavailability should also be considered.20 The intraluminal
solubility of BCS II drugs in LFs can be estimated using the in
vitro lipolysis model, and the ﬁrst-pass extraction ratio can be
assessed by performing microsomal stability assays. Based on
this, the current work proposes, for the ﬁrst time, the
combination of in vitro lipolysis and microsomal metabolism
studies for the prediction of human oral bioavailability of
lipophilic drugs administered in LFs. This novel approach, if
successful, would transform the lipolysis model from a
qualitative tool to a quantitative one. If predictive of the in
vivo response, this novel methodology could drastically reduce
the need for animal experiments, improve accuracy and
predictability for formulation design, and lead to better
designed clinical trials, hence reducing the time and cost of
industrial research and development.
For this investigation, Δ9-tetrahydrocannabinol (THC) and
cyclosporine A (CsA) were selected as model BCS class II
drugs. THC is an orally active cannabinoid which has complex
eﬀects on the central nervous system. THC is a highly lipophilic
(log P = 6.9721) and poorly water-soluble (Sw = 0.77−2.8 μg/
mL22) drug marketed under the brand name Marinol. Marinol
is approved for the treatment of anorexia in AIDS patients, as
well as for refractory nausea and vomiting in patients
undergoing chemotherapy. Marinol contains dronabinol
(synthetic THC) dissolved in sesame oil.23 CsA acts as an
immunosuppressant drug and is broadly used to prevent graft
rejection in organ transplantation patients, and for the
treatment of severe arthritis and psoriasis, among other
indications.24 CsA is characterized by moderately high
lipophilicity (log P = 3.3521) and very low solubility in aqueous
media (SW = 5 ± 2 μg/mL
25), and it is commercialized mainly
as Sandimmun Neoral, a lipid-based self-emulsifying drug
delivery system (SEDDS) of CsA. Neoral consists of CsA
dissolved in a mixture of lipids, cosolvents, and surfactant. Five
published clinical studies were selected as a set of clinical data
for the purpose of predicting the human oral bioavailability of
THC in Marinol and of CsA in Neoral.26−30
The overall aim of this work was to develop a novel
quantitative tool of oral bioavailability of BCS II drugs in LFs,
by combining in vitro lipolysis and metabolism, using Marinol
(THC) and Neoral (CsA) as model formulations.
2. EXPERIMENTAL SECTION
2.1. Materials. Sodium hydroxide solution (NaOH, 1 M),
Trizma maleate, sodium taurocholate hydrate (98% w/w), L-α-
lecithin (∼60% pure L-α-phosphatidylcholine, from egg yolk),
pancreatin powder from porcine pancreas (8 × US
Pharmacopeia speciﬁcations activity), verapamil (≥99% w/w),
dexamethasone (≥98% w/w), chlorpromazine (≥98% w/w), α-
tocopherol, Kolliphor RH 40, potassium phosphate dibasic
anhydrous (K2HPO4), potassium phosphate monobasic anhy-
drous (KH2PO4), magnesium chloride (MgCl2, ≥98% w/w),
ammonium acetate (≥99% w/w), and formic acid (∼98% v/v)
were all purchased from Sigma-Aldrich (Dorset, UK). Sodium
chloride (99.5% w/w) and nicotinamide adenine dinucleotide
phosphate tetrasodium salt hydrate (NADPH, 93% w/w) were
products from Fisher Scientiﬁc (Leicester, UK). Calcium
chloride anhydrous (93% w/w) and vitamin D3 (VitD3, 98%
w/w) were obtained from Alfa Aesar (Heysham, UK). Sesame
oil and corn oil were purchased from Acros Organics (Geel,
Belgium). Dronabinol (synthetic (−)-trans-Δ9-THC) and CsA
were products from THC Pharm GmbH (Frankfurt, Germany)
and Kemprotec Ltd. (Carnforth, UK), respectively. Cannabidiol
(CBD) was kindly donated by GW Pharmaceuticals (Cam-
bridge, UK). Propylene glycol (PG) was purchased from
Amresco (Ohio, USA). Human liver microsomes were obtained
from Gibco Invitrogen (Paisley, UK). Intestinal human
microsomes were a product from Tebu-Bio Ltd. (Peter-
borough, UK). The standard buﬀer solutions for calibration
of the pH-electrode were purchased from YSI Incorporated
(Ohio, USA) and Hanna Instruments (Rhode Island, USA). All
solvents were of high-performance liquid chromatography
(HPLC) grade or analytical grade and were used without any
further puriﬁcation.
2.2. Selection of Clinical Studies and Pharmacokinetic
Analysis: Calculation of the Observed Oral Bioavail-
ability (Fobserved) in Human Subjects. The selection of
model formulations was done based on availability of published
clinical data. An exhaustive search in the literature was
performed in order to ﬁnd publications which would provide
the necessary information to accurately reproduce the in vivo
digestion of the LF using the in vitro model. The studies were
chosen based on the following criteria: (a) volunteers had to be
dosed in the fasted state; (b) volunteers had to be healthy (no
history of renal, hepatic, or gastrointestinal diseases) adults (18
to 55 years old); (c) clear information about the exact amount
of lipidic formulation administered had to be available; and (d)
relevant pharmacokinetic data for a single oral dose and
intravenous (IV) administration had to be available.
More than 30 marketed LFs31 were screened with the aim of
ﬁnding published clinical trials that would meet the criteria
detailed above. Some LFs were not considered because sales
had been discontinued (Fortovase, saquinavir32), because more
than one active pharmaceutical ingredient was included in the
medicine (Kaletra, lopinavir and ritonavir33), or because they
were extended-release drug products (Ketas, ibudilast;34 MXL
capsules, morphine sulfate;35 and Detrol LA, tolterodine
tartrate36). Most of the LFs containing antivirals and antineo-
plastics were rejected mainly due to available trials referring to
nonhealthy volunteers, such as HIV patients (Agenerase,
amprenavir;37 Norvir, ritonavir;38 Aptivus, tipranavir;39 and
Sustiva, efavirenz40) and cancer patients (Targretin, bexar-
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otene41). Other LFs were discarded due to unavailable (Epadel,
ethyl icosapentate; and Fenogal, fenoﬁbrate), or very limited
(Avodart, dutasteride;42 and Infree S capsules, indomethacin
farnesil43) available oral pharmacokinetic data for single oral
doses. Some LFs were rejected because clinical trials included
volunteers in the fed state, and/or it was not indicated whether
the administered formulation was actually a lipidic one (Juvela
N, tocopherol nicotinate;44 Selbex, teprenone;45 Accutane,
isotretinoin;46 and Rapamune, sirolimus47). If only one single
valid study could be found, the LFs were not taken into account
either (Depakene, valproic acid;48 Cipro, ciproﬂoxacin;49
Glakay capsules, menatetrenone;50 Vesanoid, tretinoin;51
Prometrium, progesterone;52 and Hectorol, doxercalciferol53).
The LFs of testosterone undecanoate (Andriol and Restandol)
were discarded as well because the stability of this ester prodrug
in the gastrointestinal tract remains unknown.
Eventually, ﬁve medicines were short-listed: Marinol
(THC),26,27,54−58 One-Alpha capsules (alfacalcidol),59,60 Rocal-
trol (calcitriol),60,61 Heminevrin (clomethiazole edisilate),62,63
and Neoral (CsA).28−30,64−69 Marinol (sesame oil), One-Alpha
capsules (sesame oil and α-tocopherol), Rocaltrol (fractionated
triglycerides of coconut oil or palm oil) and Heminevrin
(fractionated coconut oil) are all Type I lipidic formulations,
whereas Neoral is a SEDDS consisting of lipids, surfactants and
cosolvents (Type IIIA). For the sake of formulation diversity,
we decided to select one Type I formulation (Marinol, already
available in our laboratory), and one Type III (Neoral).
The clinical studies of the selected LFs were narrowed down
further according to the inclusion/exclusion criteria explained
above. In the case of Neoral, numerous studies were rejected
because the trials were not done with healthy volunteers, who
were usually organ transplant patients,65 due to the
impossibility of conﬁrming whether the administered for-
mulation was actually Neoral,66−68 and due to impossibility of
purchasing the administered dose strength (i.e., 60 mg capsules
are not commercially available in UK).64,69 In the case of
Marinol, some studies were not considered because of the
volunteers were not healthy (cancer patients54), because the
fed/fasted state of the subjects was not indicated,58 and because
of incomplete information about the formulation, such as the
volume of coadministered oil,55,56 or the dose strength of the
capsules.57
Finally, it was possible to select ﬁve published clinical studies
that described oral administration of THC and CsA and that
fulﬁll the eligibility criteria described above. In the case of
Marinol, the studies described the administration of: (a) 2 × 10
mg capsules (20 mg THC in ∼0.5 mL sesame oil),26 and (b) 1
× 10 mg capsule (10 mg THC in ∼0.25 mL sesame oil).27
Regarding Neoral, the studies described the administration of:
(a) 2 × 100 mg capsules (200 mg CsA in 2 mL SEDDS),28,29
(b) 3 × 100 mg capsules (300 mg CsA in 3 mL SEDDS),30 and
(c) 6 × 100 mg capsules (600 mg CsA in 6 mL SEDDS).28
Data that described intravenous administration of
THC58,70−73 (Table 1) and CsA68,74 (Table 2) was collected
as well to calculate the absolute Fobserved.
2.3. In Vitro Lipolysis Studies. 2.3.1. Composition and
Preparation of Blank Lipidic Formulations. Blank formula-
tions mimicking the excipient composition of Marinol and
Neoral, but lacking the active pharmaceutical ingredients, were
prepared and lipolysed in order to generate matrixes from
which appropriate calibration curves were constructed. Marinol
blank formulation consisted of plain sesame oil.23 The exact
composition of Neoral is not fully disclosed,24 hence some T
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approximations had to be made. Based on available
information, and assuming a standard amount of DL-α-
tocopherol of 2.5 mg per unit dose,75 it was calculated that
one 100 mg/mL Neoral capsule contains, in addition to 100 mg
CsA, the following excipients: 100 mg PG, 405 mg Kolliphor
RH 40, 0.119 mL ethanol, and 0.35 mL mono-, di-, and
triglycerides of corn oil. These speciﬁed amounts of excipients
were mixed under constant stirring at 37 °C, and stored at
room temperature until used.
2.3.2. Scaling down from in Vivo to in Vitro Conditions:
Calculation of the Amount of Formulation To Disperse in
the Digestion Medium of the Lipolysis Model. It has been
suggested76 that for the assessment of the mass of soluble drug
in the small intestine an in vivo dissolution volume of 80 to 100
mL, rather than the classic 250 mL, would be more accurate.
Therefore, it was decided to follow this approach in the current
work.
The digestion medium of in vitro lipolysis model consists of
approximately 40 mL. Therefore, the amount of formulation
corresponding to each clinical study was scaled down
accordingly to match the in vivo situation, as indicated in eq 1:
= ·in vitro in vivoVolume of LF 40 mL Volume of LF
100 mL (1)
Hence, the in vivo administration of 2 × 10 mg Marinol (0.5
mL), 1 × 10 mg Marinol (0.25 mL), 2 × 100 mg Neoral (2
mL), 3 × 100 mg Neoral (3 mL), and 6 × 100 mg Neoral (6
mL) in vivo, was mimicked in the in vitro lipolysis model by
dispersing 200 μL of Marinol, 100 μL of Marinol, 800 μL of
Neoral, 1200 μL of Neoral, and 2400 μL of Neoral,
respectively.
2.3.3. Simulated Intestinal Buﬀers. Two diﬀerent intestinal
ﬂuid compositions simulating the contents of the jejunum in
the fasted state were used for lipolysis experiments. The
composition of these digestion media (Table 3) diﬀered in the
concentration of sodium taurocholate (bile salt, BS) and
phosphatidylcholine (phospholipid, PL). The “classical” buﬀer
was analogous to those previously used by our and other
lipolysis research groups,12−14,16,77,78 and consisted of higher
concentrations of surfactants in a proportion 4:1 BS/PL. On
the other hand, the “new” buﬀer, was closer to Fasted-State
Simulated Intestinal Fluid-version 2 and physiological con-
ditions, and therefore contained lower surfactant concen-
trations in a ratio 15:1 BS/PL.79
2.3.4. Experimental Procedure. In vitro lipolysis studies were
conducted as described in previous reports.12−14,16,77,78
Calculated formulation volumes were dispersed in 35.5 mL of
biorelevant medium contained in a reaction vessel with
continuous stirring and kept at 37 °C. After 15 min of
equilibration, 3.5 mL of lipase/colipase extract (containing 735
tributyrin units of lipase activity per milliliter of digest) wasT
ab
le
2.
Se
le
ct
ed
P
ha
rm
ac
ok
in
et
ic
P
ar
am
et
er
s
of
C
yc
lo
sp
or
in
e
A
af
te
r
In
tr
av
en
ou
s
an
d
O
ra
l
A
dm
in
is
tr
at
io
n,
R
ep
or
te
d
in
th
e
L
it
er
at
ur
e
In
tr
av
en
ou
s
O
ra
l
G
om
ez
et
al
.74
H
eb
er
t
et
al
.6
8
O
de
be
rg
et
al
.30
K
im
et
al
.29
M
ue
lle
r
et
al
.2
8
n
5
5
3
6
12
24
24
D
os
e
(m
g)
15
0
22
5
30
0
30
0
20
0
20
0
60
0
A
U
C
a
(n
g·
m
in
/m
L)
40
09
68
±
11
28
75
60
82
90
±
98
07
3
30
91
20
±
61
68
0
35
14
80
±
12
75
60
32
27
52
±
11
64
6
20
82
60
±
61
74
0
58
98
60
±
14
21
40
A
ve
ra
ge
A
U
C
/d
os
e
(n
g·
m
in
/m
L/
m
g)
26
88
±
61
5c
11
22
±
37
4c
12
32
±
37
1c
98
3
±
23
7b
C
Lb
(m
L/
m
in
/k
g)
5.
30
±
1.
40
4.
97
±
0.
80
A
ve
ra
ge
C
Lc
(m
L/
m
in
/k
g)
5.
14
±
1.
15
a
A
U
C
:
A
re
a
un
de
r
th
e
co
nc
en
tr
at
io
n−
tim
e
cu
rv
e;
C
L:
cl
ea
ra
nc
e.
b
V
al
ue
s
ar
e
ex
pr
es
se
d
as
m
ea
ns
±
SD
.c
V
al
ue
s
ex
pr
es
se
d
as
w
ei
gh
te
d
m
ea
ns
±
ov
er
al
l
SD
.
Table 3. Composition of the Two Diﬀerent Lipolysis Media
Used for the Intraluminal Processing of Marinol and Neoral
Concentration (mM)
Buﬀer Classical New
Trizma maleate 50 50
Sodium chloride 150 150
Calcium chloride 2 2
Sodium taurocholate 5 3
Phosphatidylcholine 0.75 0.2
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added to the mixture to initiate the enzymatic hydrolysis. A pH-
stat titrator unit (T50 Graphix, Mettler Toledo Inc., Leicester,
UK) coupled to a pH-electrode (DGi111-SC, Mettler Toledo
Inc.) was used to keep experimental pH under control (6.80 ±
0.05) by titrating the released ionised fatty acids with 1 M
NaOH solution. Each experiment was repeated six times.
Once the lipolysis process was ﬁnished, the resulting reaction
mixtures were collected in ultracentrifuge tubes (Beckman
Coulter, High Wycombe, UK) for subsequent density gradient
ultracentrifugation. The mixtures were centrifuged (Sorvall
Discovery 100SE ultracentrifuge, TH-641 rotor, Thermo
Scientiﬁc, North Carolina, USA) at ∼197000 g and 37 °C for
90 min. After centrifugation, phases were separated, collected
(sediment was resuspended in water) and stored at -80 °C until
analysis.
2.3.5. Calculation of the Predicted Fraction Absorbed
(Fabs). Since BCS II drugs are highly permeable and lipidic
formulations are thought to inhibit drug eﬄux transporters,5,6 it
was assumed that all the mass of THC and CsA solubilized in
the micellar phase (MP) would be completely absorbed. To
determine Fabs, the concentration of drug found in the MP
([Drug]MP) was multiplied times the in vivo dissolution volume
(100 mL) and divided by the administered clinical dose, as
indicated in eq 2:
= ·⎜ ⎟⎛⎝
⎞
⎠F [Drug]
mg
mL
100 mL
Clinical dose (mg)abs MP (2)
2.4. Microsomal Metabolism Stability Studies.
2.4.1. Experimental Procedure. Clearance values were
determined by applying the “in vitro half-life” approach,
which is based on the measurement of the ﬁrst-order rate
depletion constant of a drug substrate.80 Microsomal
incubations were conducted in a similar manner to that
described previously.81 Reaction mixtures consisting of 720 μL
of 100 mM aqueous potassium phosphate buﬀer (KH2PO4/
K2HPO4, pH 7.4), 240 μL of 2.5 mg/mL human microsomal
protein in phosphate buﬀer, 120 μL of 100 mM aqueous
MgCl2, and 24 μL of 0.05−0.5 mM drug substrate were placed
in a test tube under constant stirring, inside a water bath kept at
37 °C. After 3 min of preincubation, reactions were initiated by
the addition of 96 μL of 125 mM NADPH in phosphate buﬀer.
Final concentrations of each component of the reaction mixture
are listed in Table 4. Experiments were performed at least ﬁve
times, and the organic solvent concentration (acetonitrile) in
the incubation was less than 0.5% (v/v). Verapamil and
dexamethasone were used as positive and negative controls
(extensive and limited hepatic metabolism), respectively.
Control experiments without NADPH were carried out as
well to monitor the matrix eﬀect on THC and CsA metabolism.
At ﬁve speciﬁed time points (up to 30 and 60 min, for hepatic
and intestinal assays, respectively), 200 μL aliquots were
removed and added to 16 × 150 mm glass tubes containing the
appropriate internal standard in ice-cold methanol or
acetonitrile, (to precipitate the proteins and stop the reaction).
2.4.2. Determination of in Vitro Intrinsic Clearance Values.
For the determination of the depletion rate constant, kdep,
incubation data were ﬁtted to a monoexponential model, as
shown in eq 3:
= − ·C
C
e k tt
0
dep
(3)
where Ct is the concentration of the compound remaining at
each time point and C0 is the concentration of the compound at
the beginning of the incubation process. For hepatic
metabolism, the depletion rate constants obtained with
diﬀerent initial concentrations were used to calculate the
theoretical depletion constant at inﬁnitesimally low substrate
concentration (kdep,[S]→0), as indicated in eq 4:
82−84
= · −
+→
⎛
⎝⎜
⎞
⎠⎟k k 1
[S]
[S] Kdep dep S,[ ] 0 M (4)
where [S] is the substrate concentration and KM is the
Michaelis−Menten constant.
The observed in vitro intrinsic clearance (CLint) was
calculated by multiplying kdep,[S]→0 (or kdep for intestinal
metabolism) times the volume of incubation medium (V)
normalized by the amount of microsomal protein (minc) as
shown in eq 5:
=
·→k V
m
CL dep Sint
,[ ] 0
inc (5)
Subsequently, CLint values were corrected for the fraction of
drug unbound in the incubation medium (CLuint). For CsA the
extent of nonspeciﬁc binding (fuinc) was predicted using the
Austin equation85 and a logP value equal to 3.35.86 It is known
that, for highly lipophilic drugs such as THC (logP = 6.9786),
Hallifax or Austin equations lead to poor predictions.87 On the
other hand, experimental measurement of fuinc of these drugs is
also extremely challenging due to nonspeciﬁc binding.
Assuming that THC binds to serum proteins in the same
way as to microsomal proteins, it is possible to estimate THC
fuinc using eq 6:
=
− − ·
fu
fu
100 (100 X) fu100%
X%
X% (6)
where fu100% is the fraction of THC unbound in plasma
(0.010286), fuX% is the fraction of THC unbound in the
incubation media, and X is the ratio between the total
concentration of proteins in human serum (approximately 70
mg/mL88) and the microsomal concentration in the
incubations (0.5 mg/mL).
2.4.3. Calculation of the Predicted Fraction Escaping
Hepatic Metabolism (Fh). Physiologically based scaling factors
(standard human microsomal recovery of 32 mg microsomes/g
liver,89,90 and average liver weight of 22 g liver/kg body
weight91) were applied to transform CLuint (mL/min/mg
protein) into hepatic intrinsic clearances (CLuh,int, mL/min/
kg). Hepatic clearances (CLh) were next calculated based on
the “parallel-tube” model,92 as shown in eq 7:
Table 4. Concentrations of Microsomal Incubations
Components at t = 0 min
Compound Concentration
KH2PO4/K2HPO4 60 mM
MgCl2 10 mM
Test compound 0.001, 0.0025, 0.005, 0.010 mMa
Human intestinal/hepatic microsomes 0.5 mg/mL
NADPH 1 mM
aDue to limited availability of intestinal protein, intestinal metabolism
studies were performed only at a single concentration level (0.001
mM).
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= − − ·QCL (1 e )Qh h
fu CLu /b h,int (7)
where Qh is the hepatic blood ﬂow (21 mL/min/kg)
81,93 and
fub is the fraction unbound in blood. For CsA the fub value was
found in the literature (0.0494), whereas, for THC (0.0096), it
was calculated based on the fraction of drug unbound in plasma
and the blood to plasma ratio (1.60386). Fh was ﬁnally
calculated from the CLh, as indicated in eq 8:
= −F Q(1 CL / )h h h (8)
2.4.4. Calculation of the Predicted Fraction Escaping Gut
Wall Metabolism (Fg). The abundance data of the relevant
metabolizing enzymes in the small intestine (CYP2C9 for
THC, and CYP3A for CsA) were used to transform CLuint
values (mL/min/mg protein) into gut intrinsic clearances
(CLug,int, L/h). These conversion values were: 8.4 pmol
CYP2C9 and 43 pmol CYP3A4 per mg of microsomal protein,
and total CYP2C9 and CYP3A content in the small intestine of
12 and 70.5 nmol, respectively.95,96
Fg were estimated using the “Q gut” model,
97,98 as deﬁned in
eq 9:
=
+ ·
F
Q
Q fu CLug
gut
gut g g,int (9)
The fraction of drug unbound in the enterocytes (fug) is
commonly assumed to be 1, since this has been shown to
provide the greatest accuracy of prediction when using the Qgut
model.99 The gut blood ﬂow (Qgut) represents a mixture of
villous blood ﬂow (Qvilli = 18 L/h
100) and the permeability
across the enterocytes (CLperm), as indicated in eq 10:
=
·
+
Q
Q
Q
CL
CLgut
villi perm
villi perm (10)
CLperm was calculated through the eﬀective intestinal
permeability (Peff,CsA = 1.65 μm/s,
101 and Peff,THC = 7.56 μm/
s86) and the small intestine cylindrical surface area (0.66 m298).
2.5. Calculation of the Predicted Oral Bioavailability
(Fpredicted). To calculate the predicted oral bioavailability of
THC and CsA, the estimated Fabs, Fg, and Fh were combined, as
indicated in eq 11:
= · · ·F F F F(%) 100predicted abs g h (11)
2.6. Analytical procedures. 2.6.1. HPLC-UV Analysis. The
quantitative determinations of THC and CsA in lipolysis
phases, as well as verapamil and dexamethasone content in
microsomal incubations were performed using a HPLC system
(Waters Alliance 2695, Waters Corp., Milford, MA, USA)
equipped with a photodiode array UV detector (Waters 996).
Samples temperature was controlled by a ﬁtted chiller at 4 °C.
Data acquisitions and processing was carried out using
Empower 2 software (Waters).
The analysis of THC in lipolysis samples was similar to that
developed by Zgair et al.,102 with some modiﬁcations. These
changes consisted in choosing a diﬀerent internal standard
(VitD3 instead of probucol) and using 200 μL of sample
volume instead of 150 μL. Aliquots of 200 μL of MP were
mixed with 60 μL of 350 μg/mL VitD3 in acetonitrile, and
vortex-mixed for 2 min. Subsequently, 600 μL of ice-cold
acetonitrile was added, and samples were vortex-mixed for 2
min. Six hundred microliters of water was added, and samples
were vortex-mixed again for another 2 min. Next, 3 mL of n-
hexane was added, and samples were vortex-mixed for 5 min.
After centrifugation at ∼1200g (Harrier 18/80 centrifuge,
swing-out rotor, MSE, London, UK) for 15 min at room
temperature, the upper organic layer was transferred to a fresh
glass tube and evaporated under a gentle stream of nitrogen gas
at 35 °C (Techne Dri-Block Sample Concentrator, Cambridge,
UK). Residues were reconstituted in 200 μL of acetonitrile, and
10 μL was injected into the HPLC system. Both THC and
VitD3 were detected at 220 nm. The separation was achieved
using a Sonoma C18(2) 100 × 2.1 mm, 3 μm particle size
column (ES Industries, West Berlin, NJ, USA), protected by a
Phenomenex C18 4 × 2 mm guard cartridge (Phenomenex,
Macclesﬁeld, UK). The mobile phase was a mixture of
acetonitrile and water in a ratio of 75:25 (v/v). The ﬂow rate
was set at 0.3 mL/min for 40 min at 55 °C. The lowest
validated limit of quantiﬁcation was 2 μg/mL, and the linearity
of the method was conﬁrmed over a concentration range of
10−350 μg/mL based on at least 8 concentration levels, with
correlation coeﬃcient (R2) value ≥0.99.
The sample treatment of CsA lipolysis samples was similar to
that of THC samples, except for the internal standard used (20
μL of 2 mg/mL CBD in acetonitrile), the extraction solvent
(methyl tert-butyl ether), and the volume of solvent added to
reconstitute the residue (1000 μL). Both CsA and CBD were
monitored at 211 nm. The separation was achieved using a
Sonoma C18(2) 100 × 2.1 mm, 3 μm particle size column,
protected by a Phenomex C18 4 × 2 mm guard cartridge. The
mobile phase was a mixture of acetonitrile and water in a ratio
of 65:35 (v/v). The ﬂow rate was set at 0.3 mL/min for 20 min
at 60 °C. The lowest validated limit of quantiﬁcation was 50
μg/mL, and the linearity of the method was conﬁrmed over a
concentration range of 0.1−8 mg/mL based on at least 8
concentration levels, with correlation coeﬃcient (R2) value
≥0.99.
Verapamil and dexamethasone103 microsomal incubation
samples were quenched with 1000 μL 2 μM chlorpromazine in
methanol (internal standard for both compounds), vortex-
mixed with for 10 s, and then centrifuged at ∼1200g at room
temperature for 10 min. The upper organic phase was carefully
decanted into a fresh glass tubes and the solvent was
evaporated under nitrogen gas at 35 °C. The residue was
reconstituted in 150 μL of aqueous acetonitrile (50%, v/v),
vortex-mixed for 5 min, and centrifuged again at ∼1200g for 10
min. Finally, 100 μL of the resulting solutions was transferred
into HPLC vials and 20 μL was injected into the HPLC
instrument. Verapamil, dexamethasone and internal standard
were detected at 229, 240, and 254 nm, respectively. In both
cases, the separation was achieved using a Phenomenex
Gemini-NX 250 × 4 mm, 5 μm particle size column, protected
by a Phenomex C18 4 × 2 mm guard cartridge. The mobile
phase was a mixture of acetonitrile and aqueous ammonium
acetate (10 mM, pH 4.9) in a ratio of 50:50 (v/v). The ﬂow
rate was set at 0.4 mL/min for 17 min at 40 °C.
2.6.2. LC-MS/MS Analysis. The determination of THC and
CsA in microsomal incubation samples was accomplished by
means of LC-MS/MS analysis since lower limits of
quantiﬁcation had to be achieved. Microsomal metabolism
samples were treated in a similar manner to lipolysis samples.
After protein precipitation using 600 μL 1 μM internal standard
(VitD3 for THC, CBD for CsA) in acetonitrile, the procedure
of water addition, mixing, extracting solvent addition, mixing,
centrifuging, decanting and evaporating, was identical to that
described in the previous section. Eventually, samples were
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reconstituted in 100 μL of 0.1% (v/v) formic acid in
acetonitrile, and 10 μL was injected into the HPLC instrument.
Quantitative determinations were performed using a HPLC
system (Agilent 1100 Series, Agilent Technologies, Waldbronn,
Germany) equipped with a Quattro Ultima triple-quadrupole
mass spectrometer (Waters), using electrospray ionization for
ion production. Samples temperature was controlled by a ﬁtted
chiller at 4 °C. Data acquisitions and processing was carried out
using MassLynx software (Waters). Separations were achieved
on a Waters XBridge C18 75 × 2.1 mm, 2.5 μm particle size
column, at a ﬂow rate of 0.3 mL/min and at 60 °C. Elution was
conducted with 0.1% (v/v) formic acid in water/acetonitrile
90:10 (v/v) during 7 min, and 82.5:17.5 (v/v) during 3.5 min,
for THC and CsA detection, respectively. Multiple-reaction
monitoring in positive mode was used to trace ions as follows
(m/z precursor ion/product ion): THC (315.2/193.0), VitD3
(385.3/259.3), CsA (1219.7/1202.7) and CBD (315.2/193.0).
Nitrogen was used as drying and nebulization gas at ﬂow rates
of 650 L/h and 150 L/h, respectively. The desolvation and
source block temperatures were and 350 and 125 °C,
respectively. The capillary voltages were 3.6 kV and 4.5 kV,
for THC and CsA detection, respectively. The cone voltages
were 35 and 45 V for THC and VitD3 analysis, and CsA and
CBD analysis, respectively.
2.7. Statistical Analysis. All presented data are expressed
as mean ± standard deviation (SD), unless stated otherwise. A
one-way analysis of variance (ANOVA, followed by post hoc
Tukey-Kramer multiple comparison test) or an unpaired t-test
with Welch’s correction, was used for determining statistically
signiﬁcant diﬀerences among the experimental groups.
Pearson’s correlation test104,105 was performed for investigating
the strength of the association between Fobserved and Fpredicted. A
p value of 0.05 was considered the minimal level of signiﬁcance.
Statistical analyses were performed using GraphPad Prism
version 6.00 (GraphPad Software, San Diego, CA, USA).
3. RESULTS
3.1. Pharmacokinetic Analysis: Calculation of the
Observed Oral Bioavailability in Human Subjects. With
the aim of calculating the observed oral bioavailability in human
subjects after administration of THC in Marinol and of CsA in
Neoral, pharmacokinetic data were obtained from published
clinical studies (Table 1 and Table 2). The ratios of the area
under the curve values normalized by the dose, after oral and
intravenous administration, were used to calculate the absolute
oral bioavailability in the diﬀerent clinical studies. The obtained
Fobserved values are summarized in Table 5.
3.2. In Vitro Lipolysis: Prediction of the Fraction
Absorbed (Fabs). The intraluminal processing of the selected
LFs was assessed by in vitro lipolysis using two diﬀerent
digestion buﬀers. This was done to determine the eﬀect of
surfactant concentrations on the overall digestion process. The
adequate amount of LF to be dispersed in the 40-mL-volume
vessel of the digestion medium was calculated by scaling down
the amount of LF orally administered to human subjects in the
selected clinical studies and by assuming an in vivo dissolution
volume of 100 mL (see eq 1). Drug solubility in the MP
following the lipolysis process and ultracentrifugation was
determined by means of HPLC-UV.
Table 5. Absolute Oral Bioavailability Values Calculated from the Data Reported in Published Clinical Studies (Fobserved), and
Calculated with the in Vitro Lipolysis/Metabolism Approach (Fpredicted), Using Two Diﬀerent Digestion Buﬀers
a
Fpredicted (%) = Fabs·Fg·Fh Fpredicted,h (%) = Fabs·Fh Fpredicted,g (%) = Fabs·Fg
Formulation Dose Fobserved (%) Classical buﬀer New buﬀer Classical buﬀer New buﬀer Classical buﬀer New buﬀer
Marinol 2 × 10 mg THC26 4.1 ± 3.6 3.4 ± 1.3 1.3 ± 0.5 9.6 ± 3.6 3.7 ± 1.3 7.0 ± 1.2 2.7 ± 0.3
1 × 10 mg THC27 3.4 ± 3.8 8.3 ± 3.3 1.1 ± 0.5 23.3 ± 8.9 3.2 ± 1.3 17.1 ± 3.4 2.3 ± 0.6
Neoral 2 × 100 mg CsA28,29 46.5 ± 18.1 21.6 ± 1.9 40.3 ± 3.7 41.7 ± 2.6 77.9 ± 5.3 24.0 ± 1.6 44.8 ± 3.1
3 × 100 mg CsA30 41.8 ± 16.9 26.3 ± 2.5 41.0 ± 4.2 50.8 ± 3.6 79.2 ± 6.3 29.0 ± 2.1 45.5 ± 3.7
6 × 100 mg CsA28 36.6 ± 12.1 36.6 ± 3.5 47.4 ± 6.0 70.7 ± 4.9 91.6 ± 11.6 40.6 ± 2.9 52.6 ± 5.8
aPredicted values ignoring gastric metabolism (Fpredicted,h), and ignoring hepatic metabolism (Fpredicted,g, full lymphatic transport) are included as well.
Values are expressed as means ± SD.
Figure 1. Fraction of absorbed dose of tetrahydrocannabinol (THC) in Marinol (A) and of cyclosporine A (CsA) in Neoral (B) estimated from
lipolysis studies. Striped bars correspond to the lipolysis of the formulations using the “classical” buﬀer, whereas plain bars represent the “new” buﬀer.
Values are expressed as means (n = 6) ± SD. An unpaired t-test followed by Welch’s correction was used for statistical analysis. Statistically
signiﬁcantly diﬀerent: ****, p < 0.0001; **, p < 0.01.
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When the classical buﬀer was used, and the proportional
amounts of two and one 10-mg Marinol capsules (200 and 100
μL of 40 mg/mL THC in sesame oil) were digested, the THC
concentrations in MP were 40 ± 5 μg/mL and 47 ± 8 μg/mL,
respectively. Similarly, when the proportional amounts of two,
three, and six Neoral capsules (800, 1200, and 2400 μL of 100
mg/mL CsA in SEDDS) were lipolysed, the concentrations of
CsA in MP were 0.926 ± 0.012 mg/mL, 1.692 ± 0.066 mg/mL,
and 4.709 ± 0.156 mg/mL, respectively.
When the new buﬀer was used instead of a classical one, the
concentrations found in the MP were 6 ± 2 μg/mL THC, 15 ±
1 μg/mL THC, 1.729 ± 0.048 mg/mL CsA, 2.637 ± 0.134 mg/
mL CsA, and 6.103 ± 0.703 mg/mL CsA, following the
lipolysis of 200 and 100 μL of Marinol, and 800, 1200, and
2400 μL of Neoral, respectively.
As previously indicated, the working hypothesis of the in vitro
lipolysis model is that the fraction of drug dose which is
solubilized in the MP is most readily available for absorption. In
addition, THC and CsA are highly permeable drugs, and LFs
are thought to inhibit eﬄux mechanisms.5,6 Therefore, it was
assumed that all the amount of THC and CsA solubilized in the
MP would completely penetrate into the enterocytes.
Accordingly, the concentration values found in the MP were
next introduced in eq 2 to calculate the predicted Fabs
represented in Figure 1.
Statistical analysis (Figure 1) showed that there were
signiﬁcant diﬀerences (p > 0.05) in the estimated Fabs, when
the same volume of lipidic formulation was digested using
buﬀers diﬀering in the level of surfactants concentrations. It was
also shown that there were signiﬁcant diﬀerences in the
estimated Fabs among diﬀerent doses of the same formulation
when using the classical buﬀer, but no statistically signiﬁcant
diﬀerences were detected when the new buﬀer was used. The
exception was the high-dose six Neoral capsules study, which
turned up to be statistically diﬀerent from the other two Neoral
studies.
3.3. Hepatic Microsomal Metabolism: Prediction of
the Fraction Nonmetabolized in the Liver (Fh). Apart from
intraluminal solubilization, the other important factor that
limits the oral bioavailability of BCS II drugs is ﬁrst-pass
metabolism. To determine the fraction of drug dose that is not
cleared by the liver, microsomal metabolism stability studies
with human hepatic microsomes were performed. The
metabolism rates of THC and CsA at diﬀerent initial
concentrations by human liver microsomes were obtained by
applying the “in vitro half-life” approach and ﬁtting the data to
monoexponential decay regressions (see eq 3) represented in
Figure 2. These kdep values were next used to determine the
theoretical depletion constant at inﬁnitesimally low substrate
concentration (kdep,[S]→0) and the Michaelis−Menten constant
(KM), according to eq 4. For THC, kdep,[S]→0 was 0.5666 ±
0.1929 min−1, and KM was 3.76 ± 1.28 μM (R
2 = 0.91). With
regard to CsA, the calculated values were 0.0158 ± 0.0010
min−1 and 6.59 ± 0.41 μM (R2 = 0.99), for kdep,[S]→0 and KM,
respectively.
Using the microsomal concentration and the fraction
unbound in the incubation medium, kdep,[S]→0 was subsequently
transformed into intrinsic clearance (eq 5: CLuint,THC = 2.236 ±
0.761 mL/min/mg protein; CLuint,CsA = 0.078 ± 0.005 mL/
min/mg protein). Next, physiologically based scaling factors
(average microsome content in the liver, and average liver
weight per kg of body weight) were applied to transformed
CLuint into intrinsic hepatic clearance (CLuh,int). Subsequently,
the hepatic blood ﬂow and the fraction of drug unbound in
blood were introduced in the “parallel-tube” model equation to
calculate the hepatic clearance (eq 7: CLh,THC = 10.77 ± 3.67
mL/min/kg; CLh,CsA = 2.08 ± 0.13 mL/min/kg). Finally, it was
estimated that approximately 49% and 90% of THC and CsA
molecules, respectively, would escape ﬁrst-pass metabolism in
the liver (eq 8: Fh,THC = 0.487 ± 0.166; Fh,CsA = 0.901 ± 0.055).
3.4. Intestinal Microsomal Metabolism: Prediction of
the Fraction Nonmetabolized in the Gut (Fg). First-pass
metabolism can occur not only in the liver, but also within the
enterocytes in the gut wall. Similarly to the hepatic metabolism
experimental procedure, the calculation of the fraction of the
drug dose that escapes metabolism in the gut was performed by
means of microsomal metabolism stability studies with human
intestinal microsomes. The metabolism rates of THC and CsA
by human intestinal microsomes were obtained from the ﬁtted
monoexponential decay regressions represented in Figure 3.
The obtained kdep values were 0.0478 ± 0.0046 min
−1 (R2 =
0.999) and 0.0060 ± 0.0013 min−1 (R2 = 0.963), for THC and
CsA, respectively.
Again, the microsomal concentration and the fraction
unbound in the incubation medium were used to transform
kdep into intrinsic clearance (eq 5: CLuint,THC = 0.188 ± 0.018
mL/min/mg protein; CLuint,CsA = 0.031 ± 0.002 mL/min/mg
protein). Next, relative abundance data of CYP2C9 and CYP3A
in the gut were used to determine the gut intrinsic clearance
values (CLug,THC = 16.2 ± 1.5 L/h; CLug,CsA = 3.1 ± 0.2 L/h).
The “Q gut” model, which accounts for mucosal blood ﬂow and
permeability across the enterocytes, was applied to ﬁnally
Figure 2. Depletion curves at diﬀerent concentration levels derived from hepatic microsomal incubations of tetrahydrocannabinol (A) and
cyclosporine A (B). The ratio between the drug concentration remaining at each time point (C) and the concentration of drug at the beginning of
the incubation process (C0) is represented versus time. Values are expressed as means (n = 6) ± SD.
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calculate Fg (eq 9). It was estimated that around 36% and 52%
of THC and CsA molecules, respectively, would escape ﬁrst-
pass metabolism in the small intestine (Fg,THC = 0.358 ± 0.034;
Fg,CsA = 0.517 ± 0.033).
3.5. Linking in Vitro Lipolysis and Metabolism Studies:
Prediction of the Oral Bioavailability (Fpredicted). The
estimated absorbed (Fabs) and nonmetabolized (Fg·Fh) fractions
were combined for the calculation of the predicted oral
bioavailability, as indicated in eq 11. Bioavailability results are
summarized in Table 5. Pearson’s correlation test was used for
the measurement of the strength of the association between
Fobserved and Fpredicted. Statistical analysis showed there was
signiﬁcant correlation between Fobserved and Fpredicted when the
new buﬀer was used (Pearson’s r = 0.9638; p = 0.0088), but
that was not the case for the classical buﬀer (Pearson’s r =
0.8291; p = 0.0819).
4. DISCUSSION
LFs are mainly used for the oral delivery of BCS II drugs.
Intestinal micellar solubilization and ﬁrst-pass metabolism
(rather than membrane permeability) are the main barriers to
the oral bioavailability of BCS II drugs. In vitro, the intraluminal
solubility of BCS II drugs administered in LFs can be estimated
using the lipolysis model, whereas the ﬁrst-pass extraction ratio
can be assessed by performing microsomal stability assays.
Previous studies in the in vitro lipolysis ﬁeld have focused on
correlating the percentage of drug solubilized in the aqueous
micellar phase with the drug exposure after oral administration
of the tested lipidic formulation in laboratory animals.13,15,18 So
far, the obtained relationships have been qualitative in nature,
and have been proven useful for rank-ordering formulations.
The work presented herein proposes a novel combination of in
vitro lipolysis and microsomal metabolism studies for the
quantitative prediction of human oral bioavailability of BCS II
drugs administered in LFs. This novel approach has the
potential to transform the lipolysis model studies from a
qualitative tool to a quantitative one.
4.1. Selection of Model Lipidic Formulations and
Clinical Studies. Two model LFs, Marinol (THC dissolved in
sesame oil) and Neoral (CsA dissolved in a mixture of lipids,
surfactants, and cosolvents, which upon mild agitation form
SEDDS), were selected for evaluation based on the availability
of published clinical data. Both THC and CsA belong to class II
of the BCS, and are characterized by poor aqueous solubility
and moderate to high lipophilicity.
As mentioned above, an extensive literature search was
carried out to ﬁnd articles that would provide critical
information for our purposes. One of the challenges was the
high variability in pharmacokinetic parameters in these clinical
studies, especially in the case of THC. This variability could be
partially due to the diﬀerent analytical methods used, which
included radioactivity. It was required that volunteers were
dosed in the fasted state (the lipolysis medium consists of
simulated intestinal ﬂuids in the fasted state) and that the exact
amount of orally administered formulation was clearly stated
(to calculate the proportional amount of LF to digest in the
lipolysis model). On the other hand, it was essential that these
articles would include relevant pharmacokinetic data allowing
the calculation of the absolute oral bioavailability in human
subjects. Numerous studies had to be discarded from the list of
relevant in vivo information due to the poor state of health of
the volunteers (transplant,65 and cancer54 patients), because the
fed or fasted state of the subjects was not indicated,58 and
because of incomplete and/or uncertain information about the
formulation, such as the volume of coadministered oil,55,56 or
the dose strength.28,57,69
Eventually, based on the above criteria, ﬁve published clinical
studies were selected with the aim of predicting the human oral
bioavailability of THC in Marinol26,27 (Table 1) and of CsA in
Neoral28−30 (Table 2).
4.2. In Vitro Lipolysis: Prediction of the Fraction
Absorbed (Fabs). 4.2.1. Scaling down Doses from in Vivo to
in Vitro Conditions. To assess the intraluminal processing of
THC and CsA lipidic formulations, and to predict Fabs, in vitro
lipolysis experiments were carried out. For the estimation of the
amount of drug solubilized in the small intestine, two diﬀerent
in vivo dissolution volumes were initially considered: 250 and
100 mL. The ﬁrst value corresponds to the amount of water
given to volunteers in clinical trials, and it has been used by the
BCS as the standard volume for assessing the maximum
solubility of drugs in the fasted state.106 However, the latest
publications76 suggest that while 250 mL is the reasonable
volume for the assessment of the solubility of drugs in the
stomach, it might be too high for the estimation of drug
solubility in the small intestine. Mudie et al. suggested in their
work using a volume of 80−100 mL instead of 250 mL. Lipid
digestion and absorption occur almost entirely in the upper part
of the small intestine;20 therefore, 100-mL volume was deemed
appropriate in our studies. The digestion medium of the in vitro
lipolysis model has approximately 40-mL volume; therefore, the
amounts of Marinol (40 mg/mL THC) and Neoral (100 mg/
mL CsA) were scaled down accordingly to match the in vivo
situation.
4.2.2. Eﬀect of Surfactant Levels on in Vitro Drug
Solubilization. Initially, a lipolysis buﬀer analogous to those
previously used by ours and other lipolysis research
groups,12−14,16,77,78 characterized by high concentrations of
BSs and PLs (Table 3), was used for digestion of the
formulations. According to literature data23,28 and the
pharmacokinetic analysis performed, both Marinol and Neoral
showed approximate dose proportionality. However, Fabs results
(Figure 1) suggested changes in the percentage absorbed
dependent on dose for both formulations. Hence, it was
apparent that a reﬁnement in the lipolysis conditions was
needed. Following the lead of other research groups,107
surfactant levels were reduced down to more biorelevant
Figure 3. Depletion curves derived from intestinal microsomal
incubations of 1 μM tetrahydrocannabinol (diamonds) and 1 μM
cyclosporine A (squares). The ratio between the drug concentration
remaining at each time point (C) and the concentration of drug at the
beginning of the incubation process (C0) is represented versus time.
Values are expressed as means (n = 6) ± SD.
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concentrations,79 and lipolysis experiments were performed
again. Interestingly, reduction in surfactant concentrations
caused opposite eﬀects for the two tested model drugs. The
solubilized fractions of THC decreased (Figure 1A), whereas
the solubilized fractions of CsA increased (Figure 1B). Marinol
is a Type I lipidic formulation;108 therefore, it highly depends
on the presence of BSs and PLs to create mixed micelles within
which THC and lipolytic products (fatty acids and 2-
monoglycerides) are solubilized. Therefore, the lower the
surfactant concentration is, the fewer the number of micelles is,
and the lower the solubilized fraction would be. On the other
hand, Neoral is a SEDDS (Type IIIA lipidic formulation); for
this reason it does not require surfactant agents to generate
solubilizing structures for CsA. The observed variable and
reduced solubility of CsA when using the “classical” buﬀer
could be explained by the inhibitory eﬀect of BSs and PLs in
SEDDS formation. An excess of BS- and PL-derived micellar
structures would lead to a higher entrapment of Neoral
components, thus reducing the number of SEDDS particles and
decreasing the inherent solubilization capacity of Neoral.
Results derived from the use of the “new” more biorelevant
buﬀer proved to be more consistent within formulations and
showed no statistically signiﬁcant diﬀerences between diﬀerent
formulation strengths, as seems to occur in vivo.28 The only
exception was the study mimicking the administration of a very
high-dose of CsA (six Neoral capsules), which proved to be
statistically diﬀerent from the other two CsA studies.
Interestingly, a higher dose of digested Neoral in vitro led to
a higher fraction of solubilized dose, whereas in vivo the case
was the opposite. This phenomenon has already been
witnessed by Berthelsen et al.107 when working with Kolliphor
RH 40 (the main surfactant component in Neoral), and it was
explained by the micellar trapping hypothesis. According to this
hypothesis, the reduced bioavailability in vivo when using very
high levels of Kolliphor RH 40 might be caused by a higher
amount of undigested surfactant trapping the drug, thus
decreasing the amount of drug available for intestinal
permeation.
After lipolysis and subsequent centrifugation, three distinct
layers were obtained: an upper undigested lipid phase (only
present in Marinol experiments), a middle aqueous-micellar
phase, and a lower sediment phase. The general assumption
made by researchers working with the in vitro lipolysis model is
that the fraction of drug dose which is solubilized in the
micellar phase is most readily available for absorption. This
assumption represents an oversimpliﬁcation of the absorption
process, as drug contained in micelles could precipitate in the
lower part of the small intestine. Arguably, the estimated
fraction of absorbed drug could be slightly overestimated due to
incomplete permeability and the action of eﬄux transporters
(especially P-glycoprotein) expressed on the apical side of
enterocytes. In terms of permeability, THC and CsA belong to
class II of the BCS; thus, their membrane permeability is high,
mainly passive, and a function of lipophilicity (Peff = 7.56 and
1.65 μm/s, for THC86 and CsA,101 respectively). Therefore, it
is expected that most of the fraction of solubilized dose would
cross the apical membrane. With regard to eﬄux proteins, it has
been suggested that high drug permeability would lead to rapid
permeation into the enterocytes, making the contribution of
intestinal uptake transporters generally insigniﬁcant.109 Fur-
thermore, Ingels et al.5 and Konishi et al.6 have reported the
inhibitory eﬀect of monoglycerides on P-glycoprotein activity.
Based on this evidence, it can be assumed that eﬄux
transporters do not play a role in the bioavailability of BCS
II drugs delivered in LFs.
4.3. Microsomal Stability Studies: Prediction of the
Fraction Escaping First-Pass Metabolism in the Liver
(Fh). Since the aim of this study was to quantitatively predict
the absolute bioavailability, it was evident that lipolysis results
alone were not suﬃcient for this goal. Thus, a hepatic
metabolism phase has been introduced to account for the
loss of drug due to ﬁrst-pass metabolism in the liver.
In humans, CYP2C9110,111 and CYP3A4112,113 have been
identiﬁed as the main enzymes involved in THC and CsA
metabolism, respectively. CYP2C9 hydroxylases THC to 11-
hydroxy-THC, which may undergo further oxidation to form
the carboxylic acid 11-nor-9-carboxy-THC. CYP3A4 catalyzes
CsA metabolism through the monohydroxylation of amino
acids 1 or 9, or the N-demethylation of amino acid 4.114,115
The fraction of drug that escapes ﬁrst-pass metabolism in the
liver was determined in this work by using human liver
microsomes and applying the “in vitro half-life” approach. To
conﬁrm the correct experimental setup, the metabolism of
positive (verapamil) and negative (dexamethasone) control
compounds were assessed. The elimination rate constant values
calculated for the control compounds (kverapamil = 0.066 ± 0.002
min−1, kdexamethasone = 0.004 ± 0.001 min
−1) were in accordance
with those characteristic of highly (verapamil) and poorly
(dexamethasone) metabolized drugs, and were comparable to
those values obtained in previous reports with similar
experimental conditions.81,94 The application of the half-life
method to estimate quantitatively the metabolism rate is only
valid under the assumption that C0 is well below KM. When KM
is unknown, and a drug is metabolized in several positions
leading to an unknown number of metabolites, the rate of
metabolism can still be determined by using the “multiple
depletion curve method”.82−84 This approach consists in
generating drug depletion curves at several concentrations
and subsequently extrapolate the rate of metabolism at
inﬁnitesimally low concentration (kdep,[S]→0, eq 4). Accordingly,
kdep,[S]→0 was calculated for THC and CsA by incubating the
drugs in hepatic microsomal medium at 4 concentration levels.
The obtained kdep,[S]→0 values were then transformed into
hepatic clearance data, through corrections for the fraction of
drug unbound to microsomes and to blood proteins,
physiological scaling factors, and the application of the “parallel
tube” model. In the case of THC, the calculated CLh (10.8 ±
3.7 mL/min/kg) was slightly higher, but within the same range
as the total clearance reported in clinical studies after
intravenous administration of THC (Table 2). For CsA, the
estimated CLh (2.1 ± 0.1 mL/min/kg) was lower than that
calculated from literature pharmacokinetic data (Table 3), and
this might be due to CsA being metabolized by other organs in
addition to the liver when administered intravenously.
Eventually, CLh data were transformed into the fraction
nonmetabolized in the liver. When Fabs and Fh values were
combined, the in vitro lipolysis/hepatic metabolism approach
did not suﬃciently predict the in vivo performance of Marinol
and Neoral using either of the two buﬀers (Table 5). CsA
bioavailability was remarkably overestimated, and this fact could
be explained by the extensive extraction that the drug suﬀers at
the gut wall.116
4.4. Microsomal Stability Studies: Prediction of the
Fraction Escaping First-Pass Metabolism in the Gut (Fg).
Based on the above results, it was suggested that the accuracy of
our predictions could be improved by inclusion of an intestinal
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metabolism phase. Therefore, depletion drug assays in gut
microsomal media were next performed. Due to the limited
availability of intestinal protein, these studies were done at a
single concentration level (1 μM). Similar to hepatic
metabolism, the intrinsic clearance derived from microsomal
incubations was transformed into intestinal clearance and
fraction nonmetabolized, by applying the “Q gut” model.98
Results derived from CsA experiments (CLuint = 31 μL/min/
mg; Fg = 0.52) were in agreement with those reported by other
researchers (CLuint = 27.7 μL/min/mg;
95 Fg = 0.53
98). It is
important to note that these intestinal clearance values might
have been overestimated, as it has been suggested that lipidic
excipients may reduce gut metabolism.9,117 The “drug eﬄux-
metabolism alliance”118,119 proposes that eﬄux increases the
time available for enterocyte-based metabolism. Accordingly,
the impact of lipidic excipients on eﬄux proteins might reduce
the time available for metabolism, and thus decrease
presystemic extraction.
4.5. In Vitro Lipolysis/Metabolism Approach: Predic-
tion of the Oral Bioavailability (Fpredicted). Finally, by
combining the fractions of drug absorbed and nonmetabolized,
it was possible to propose estimated oral bioavailability values
of THC in Marinol and of CsA in Neoral for diﬀerent dose
levels (Table 5). Pearson’s correlation test showed that there
was a strong correlation between Fobserved and Fpredicted values
only when Fabs was calculated with the new buﬀer.
In the case of Marinol, the bioavailability was slightly
underestimated, but within the range of the clinical values. This
underestimation could be attributed to lymphatic transport. As
mentioned before, when dealing with oral absorption of highly
lipophilic drugs coadministered with long-chain triglycerides,
such as THC in Marinol, the lymphatic route should be taken
into consideration. Drugs absorbed via the intestinal lymphatic
system are protected from hepatic ﬁrst-pass metabolism since
the mesenteric lymph enters the systemic circulation, bypassing
the liver. However, Trevaskis et al.120 suggested that drugs
transported via intestinal lymphatics cannot avoid enterocyte-
based metabolism, unless extremely large quantities of lipids are
administered. Drug association with chylomicrons in the
enterocyte is an essential step in the lymphatic absorption
pathway.121,122 Accordingly, because the vast majority of THC
absorbed would associate with chylomicrons,123 and be
transported through the lymph, the estimated oral bioavail-
ability of Marinol could be calculated just taking into account
the fractions absorbed and not metabolized in the gut (Fabs·Fg).
The Fpredicted values obtained ignoring the hepatic phase (2.7 ±
0.3% and 2.3 ± 0.6%, for Naef et al. and Goskonda et al.
studies, respectively) were indeed closer to the average Fobserved
ones, which suggests the contribution of lymphatic transport to
THC oral bioavailability.
In the case of Neoral, the bioavailability estimations for Kim
et al. and Odeberg et al. studies were extremely accurate. When
the digestion of exceptionally high doses of formulation was
mimicked (Mueller et al. study), the in vitro lipolysis/
metabolism approach did not suﬃciently predict the clinical
value. As discussed before, this is most probably due to CsA
micellar trapping occurring when very high amounts of
Kolliphor RH 40 are used. This phenomenon cannot be
accurately accounted for with the in vitro lipolysis model, and
thus it leads to an overestimation of Fabs and subsequent
Fpredicted.
The general accuracy of the bioavailability predicted values,
and the strong correlation shown with the clinical ones,
suggests that the novel in vitro lipolysis/metabolism approach
could satisfactory quantitatively estimate the oral bioavailability
of BCS II drugs administered in LFs. However, the in vitro
lipolysis model is not able to predict the micellar trapping of
drugs caused by undigested lipidic excipients in vivo. Therefore,
the lipolysis/metabolism approach might have limited applic-
ability when extremely high dose levels of surfactants are
ingested.
5. CONCLUSIONS
In vitro lipolysis and microsomal metabolism studies have been
combined for the ﬁrst time with the aim to quantitative predict
the human oral bioavailability of BCS II drugs administered in
LFs. This novel approach led to reasonably good predictions of
the oral bioavailability of THC in Marinol and of the CsA in
Neoral (model formulations) based on the similarity between
the predicted bioavailability values and those reported in
clinical trials after oral administration of the tested formulations
to human subjects.
The use of a digestion buﬀer with surfactant concentrations
closer to biorelevant conditions resulted in more accurate
predictions of oral bioavailability in comparison to data derived
from the classical buﬀer previously used in in vitro lipolysis
studies.
The digestion of very high dose levels of surfactants might
represent a limitation to this novel approach, since the in vitro
lipolysis could not account for the micellar trapping
phenomenon that could occur in vivo.
The work presented herein suggests that the novel in vitro
lipolysis/metabolism approach has potential to transform the in
vitro lipolysis studies from a qualitative tool to a quantitative
one. Further analyses with additional BCS II drugs adminis-
tered in LFs might be needed to conﬁrm the predictive power
of the in vitro lipolysis/metabolism approach.
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Drug Delivery and Rational Formulation Design for Lipophilic Drugs
with Low Oral Bioavailability, Applied to Cyclosporine. Eur. J. Pharm.
Sci. 2003, 20 (4−5), 375−382.
(31) Strickley, R. G. Currently Marketed Oral Lipid-Based Dosage
Forms: Drug Products and Excipients. In Oral Lipid-Based
Formulations: Enhancing the Bioavailability of Poorly Water-Soluble
Drugs; Hauss, D. J., Ed.; Bristol-Myers Squibb Company: Princeton,
New Jersey, USA, 2007.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.6b00597
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
L
(32) Roche to discontinue the sale and distribution of Fortovase
(saquinavir). News Medical. http://www.news-medical.net/news/
2005/05/18/10187.aspx.
(33) AbbVie Inc. Kaletra® (Lopinavir/ritonavir). Available at:
Https://www.kaletra.com/ (Accessed: June 2016). 2015.
(34) Kyorin Pharmaceutical Co. Ketas® (Ibudilast). Available at:
Http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/KETAS_
Capsules.pdf (Accessed: May 2016). 2013.
(35) Napp Pharmaceuticals. MXL® Capsules (Morphine Sulphate).
Avai lable at : http://www.chardeh.com.tw/ﬁ le/Product/
201302191405252687.pdf (Accessed: May 2016).
(36) Pﬁzer - Pharmacia and Upjohn Company. Detrol® LA
(Tolterodine Tartrate). Available at: http://labeling.pﬁzer.com/
showlabeling.aspx?id=719 (Accessed: May 2016). 2013.
(37) RxList Inc. AGENERASE® (Amprenavir) Capsules, Available
at: Http://www.rxlist.com/agenerase-Drug.htm (Accessed on June
2016). 2014.
(38) U.S. Food and Drug Administration. Norvir® (Ritonavir),
Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/
2011/020945s032lbl.pdf (Accessed: May 2016). 2016.
(39) U.S. Food and Drug Administration. APTIVUS® (Tipranavir).
Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/
2011/021814s011lbl.pdf (Accessed: June 2016). 2011.
(40) Csajka, C.; Marzolini, C.; Fattinger, K.; Dećosterd, L. A.; Fellay,
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